ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Francina Agosti contributed 17 entries already.
Next-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding immune reactions (seen with many viral vectors) or undesired organ accumulation (evidenced with LNPs in the liver). Scientists are now harnessing a technology that could overcome these hurdles by using vesicles that cells naturally produce: exosomes.
Last weekend, from August 28 to 31, the European Society of Cardiology (ESC) held its annual congress in Munich. For the biotech industry, ESC 2026 delivered a mixed bag: a cardiac myosin inhibitor opening a patient population with no approved therapies, long-term validation for its main competitor, a gene silencer stumbling in ATTR-CM countered by an siRNA triumph in severe hypertriglyceridemia, and GLP-1 drugs quietly earning a place in the new heart failure guidelines. Here are the five stories that mattered most.
With an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis.
Parisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.
Paris-based Enodia Therapeutics announced the acquisition of preclinical assets from San Francisco-based Kezar Life Sciences’ pipeline. Both companies are developers of small molecules that target protein degradation, a field that is attracting significant attention for its potential to treat previously intractable diseases.
The European Innovation Council (EIC) has funded the collaborative GLIOBREAK project, bringing together Swedish biotech Beactica Therapeutics and the Belgian KU Leuven Institute for Single-Cell Omics (LISCO) to advance Beactica’s small-molecule candidate, BEA-17, as a precision immunotherapy for glioblastoma, the most common and aggressive form of brain cancer, which currently has limited treatment options.
Stockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab).
Swedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases.
French biotech company Sensorion announced today a €60 million (about $72 million) reserved offering including a €20 million strategic investment from Sanofi. The remaining €40 million subscribed by existing shareholders Redmile Group, Artal (advised by Invus), and Sofinnova Partners, alongside new investors including Cormorant Asset Management, Coastlands Capital, and Sphera Healthcare, which are leading US Healthcare Specialists funds.
The transatlantic venture firm Epidarex Capital has reached a first close of more than $145 million (approximately €121.6 million) to focus on company creation and early-stage investments across the UK and the US.